Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

<i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

Steven J. McClue, David Blake, Rosemary G. Clarke et al. · International Journal of Cancer · 2002 · 363 citations · Full text

Medicine, Oncology, Pharmacology +15

<i>N</i>-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. <i>N</i>-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

Raj N. Misra, Hai‐Yun Xiao, Kyoung S. Kim et al. · Journal of Medicinal Chemistry · 2004 · 251 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +7

AZ703, an Imidazo[1,2-<i>a</i>]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9

Dongpo Cai, Kate F. Byth, Geoffrey I. Shapiro · Cancer Research · 2006 · 75 citations

Medicine, Oncology, Pharmacology +17

Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2

D.S. Williamson, Martin J. Parratt, Justin Bower et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 70 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

Keith C. Bible, Janet L. Lensing, Sacha A. Nelson et al. · Clinical Cancer Research · 2005 · 64 citations

Medicine, Oncology, Pharmacology +17